Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osteoporosis and fragility fracture burden in Asia Pacific: Key findings from the APCO-IOF Asia Pacific Regional Audit.

Osteoporosis and sarcopenia·2026
Same author

Regional data, global lessons: what the Asia-Pacific osteoporosis audit teaches the world.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Albumin-adjusted ("corrected") calcium should no longer be reported: a position statement from the Joint IOF Working Group and IFCC Committee on Bone Metabolism and EFLM Committee on CKD.

Clinical chemistry and laboratory medicine·2026
Same author

Forearm BMD predicts fracture independently of FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Caffeic Acid, Reduced Glutathione, and Ferric Iron Addition Effects on the Redox Potential of Model Wine Solutions.

Molecules (Basel, Switzerland)·2026
Same author

Adjusting fracture probability according to duration of diabetes: the Manitoba BMD Registry.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026

Related Experiment Video

Updated: Jun 4, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Bisphosphonates in oncology.

Robert E Coleman1, Eugene V McCloskey

  • 1Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK. r.e.coleman@sheffield.ac.uk

Bone
|February 16, 2011
PubMed
Summary
This summary is machine-generated.

Bisphosphonates significantly reduce skeletal morbidity and bone pain in cancer patients by 30-50%. These agents also help prevent bone loss from cancer treatments, with generally mild side effects.

Related Experiment Videos

Last Updated: Jun 4, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metabolism

Background:

  • Bone metastases cause significant morbidity, impacting quality of life and healthcare resources.
  • Bisphosphonates are effective in reducing skeletal morbidity by 30-50% in multiple myeloma and solid tumors.
  • Their use is expanding alongside cancer therapies to prevent skeletal complications and bone pain.

Purpose of the Study:

  • To review the role of bisphosphonates in managing bone health during cancer treatment.
  • To highlight their efficacy in preventing skeletal-related events and bone loss.
  • To discuss their potential in disrupting the metastatic process and reducing recurrence risk.

Main Methods:

  • Literature review of bisphosphonate use in oncology.
  • Analysis of clinical data on skeletal morbidity reduction.
  • Examination of preclinical rationale for anti-metastatic effects.

Main Results:

  • Bisphosphonates reduce skeletal morbidity by 30-50% and alleviate bone pain.
  • They are crucial in preventing bone loss associated with chemotherapy, aromatase inhibitors, and androgen deprivation therapy.
  • Emerging data suggest adjuvant bisphosphonates may disrupt metastasis and reduce recurrence in certain patient groups.

Conclusions:

  • Bisphosphonates are a cornerstone in managing bone health in cancer patients, offering significant benefits with generally mild adverse events.
  • Their use is vital for preventing skeletal complications and managing treatment-induced bone loss.
  • Bisphosphonates show promise in modifying disease course and reducing cancer recurrence.